Altimmune, inc. (ALT) 2025Q4 financial report shows the latest P/E ratio is -5.23, which is significantly higher than the past 5-year average. This reflects the market’s high expectations for the company’s future growth, resulting in a high valuation status. Such a high P/E ratio usually means the market expects the company to continue delivering strong results, but it also implies a high performance bar for the future. It is recommended to also monitor revenue and cash flow performance to determine if the high valuation is supported by fundamentals; if revenue, cash flow, and profits are all growing, the fundamentals are solid, but if there is a disconnect, watch for possible over-optimism. Reviewing profitability ratios can further clarify the company’s capital efficiency. Using Growin AI Value Analysis and peer comparison can help understand the company’s industry positioning and financial health.